MannKind Corporation has announced the appointment of former Mylan CMO Raymond Urbanski as its Chief Medical Officer. Urbanski has also held positions at Metabolix, Pfizer, and Suntory, with experience in drug development for oncology, rheumatology, cardiology, endocrinology, and immunology.
MannKind CEO Hakan Edstrom commented, “Dr. Urbanski is a terrific addition to our team and I am very pleased to have a person of his caliber as part of the organization. Ray’s experience in drug development across multiple therapeutic areas, combined with his proven leadership capabilities, will be invaluable to us as we drive growth through our product technology platforms.
The company also said that as of June 30, 2015, shipments of Afrezza inhaled insulin were $5.9 million for the previous 3 months and $13.0 million for 6 months. MannKind and its partner Sanofi launched Afrezza in the US in February 2015.
Read the MannKind press release on the appointment of Raymond Urbanski.
Read the MannKind press release on 2nd quarter 2015 results.
